Showing 20 of 83 recruiting trials for “t-cell-large-granular-lymphocyte-leukemia”
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL
👨⚕️ Maike Buchner-Mayr, PD Dr., Technisch Universität München📍 1 site📅 Started Jan 2024View details ↗
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
RecruitingNCT06131801 ↗
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
👨⚕️ Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati📍 5 sites📅 Started Nov 2023View details ↗
RecruitingNCT06125795 ↗
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
👨⚕️ Jennifer A Woyach, MD, Ohio State University Comprehensive Cancer Center📍 3 sites📅 Started Jul 2023View details ↗
RecruitingNCT05978141 ↗
A Registry for People With T-cell Lymphoma
👨⚕️ Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center📍 26 sites📅 Started Jul 2023View details ↗
RecruitingNCT06203652 ↗
The Pathogenesis and Prognostic Factors of Lymphoma
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
👨⚕️ Mazyar Shadman, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started May 2023View details ↗
Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Vaccine Responses in Patients With B Cell Malignancies
👨⚕️ Adrian U Wiestner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Sep 2022View details ↗
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
👨⚕️ Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company📍 144 sites📅 Started Jul 2022View details ↗
RecruitingNCT04785989 ↗
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
👨⚕️ Christopher Fletcher, MD, School of Medicine and Public Health, University of Wisconsin, Madison📍 1 site📅 Started Jun 2022View details ↗
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →